Skip to main
LYEL

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma (LYEL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lyell Immunopharma is a promising company with potential for growth in the oncology sector through their novel CAR T-cell therapies for LBCL and solid tumors. The company may face some setbacks due to delays in manufacturing, but its strong leadership and focus on commercialization make it a strong competitor in the CAR T market. With the growing demand for CAR T therapies, Lyell Immunopharma has the potential to secure additional funding and become a leader in the field. Their patented technology and clinical development progress put them in a strong position for success.

Bears say

Lyell Immunopharma is executing a bold strategy to commercialize its CAR-T candidate, ronde-cel, in DLBCL and LYL273 in 3rd line mCRC. However, there are potential safety concerns and regulatory headwinds that may delay expected filing dates, resulting in a lower probability of success for these programs. Additionally, the potential market size for both products is relatively small compared to other commercially successful CAR-T therapies.

Lyell Immunopharma (LYEL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lyell Immunopharma (LYEL) Forecast

Analysts have given Lyell Immunopharma (LYEL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Lyell Immunopharma (LYEL) has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lyell Immunopharma (LYEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.